Cargando…
The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence
Global interest in the non‐intoxicating cannabis constituent, cannabidiol (CBD), is increasing with claims of therapeutic effects across a diversity of health conditions. At present, there is sufficient clinical trial evidence to support the use of high oral doses of CBD (e.g., 10–50 mg/kg) in treat...
Autores principales: | Arnold, Jonathon C., McCartney, Danielle, Suraev, Anastasia, McGregor, Iain S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841308/ https://www.ncbi.nlm.nih.gov/pubmed/36259271 http://dx.doi.org/10.1111/cts.13425 |
Ejemplares similares
-
Cannabidiol and Sports Performance: a Narrative Review of Relevant Evidence and Recommendations for Future Research
por: McCartney, Danielle, et al.
Publicado: (2020) -
Effects of cannabidiol on simulated driving and cognitive performance: A dose-ranging randomised controlled trial
por: McCartney, Danielle, et al.
Publicado: (2022) -
The “Next Day” Effects of Cannabis Use: A Systematic Review
por: McCartney, Danielle, et al.
Publicado: (2023) -
Orally administered cannabidiol does not produce false‐positive tests for Δ(9)‐tetrahydrocannabinol on the Securetec DrugWipe® 5S or Dräger DrugTest® 5000
por: McCartney, Danielle, et al.
Publicado: (2021) -
Cannabidiol but not cannabidiolic acid reduces behavioural sensitisation to methamphetamine in rats, at pharmacologically effective doses
por: Umpierrez, Laísa S., et al.
Publicado: (2022)